These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7163813)

  • 1. Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Morgan LR; Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):66-70. PubMed ID: 7163813
    [No Abstract]   [Full Text] [Related]  

  • 2. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Costanzi JJ; Morgan LR; Hokanson J
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):61-5. PubMed ID: 6298945
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of ifosfamide toxicity using dose fractionation.
    Rodriguez V; Bodey GP; Freireich EJ; McCredie KB; McKelvey EM; Tashima CK
    Cancer Res; 1976 Aug; 36(8):2945-8. PubMed ID: 1277203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
    Creaven PJ; Allen LM; Cohen MH; Nelson RL
    Cancer Treat Rep; 1976 Apr; 60(4):445-9. PubMed ID: 1277220
    [No Abstract]   [Full Text] [Related]  

  • 5. Use and safety of high-dose ifosfamide.
    Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ifosfamide in the treatment of small cell carcinoma of the lung].
    Mukouda K; Morikawa E; Hasegawa K; Noumi K; Ohmura T; Mishima Y; Kawamoto M; Inagaki A; Kamitsuna A; Yamakido M; Nishimoto Y; Koyama T; Katsuta S
    Gan To Kagaku Ryoho; 1983 May; 10(5):1293-8. PubMed ID: 6307164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    Nelson RL; Creaven PJ; Cohen MH; Fossieck BE
    Eur J Cancer (1965); 1976 Mar; 12(3):195-8. PubMed ID: 780113
    [No Abstract]   [Full Text] [Related]  

  • 8. Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Morgan LR; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):56-60. PubMed ID: 6298944
    [No Abstract]   [Full Text] [Related]  

  • 9. Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
    Costanzi JJ; Gagliano R; Loukas D; Panettiere FJ; Hokanson JA
    Cancer; 1978 May; 41(5):1715-9. PubMed ID: 206339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide in advanced osteosarcoma.
    Marti C; Kroner T; Remagen W; Berchtold W; Cserhati M; Varini M
    Cancer Treat Rep; 1985 Jan; 69(1):115-7. PubMed ID: 3855382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Holoye PY; Duelge J; Hansen RM; Ritch PS; Anderson T
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):66-71. PubMed ID: 6836329
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Slavik M; Saiers JH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):62-5. PubMed ID: 6836328
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide toxicity in Ugandan and American patients with malignant lymphoma.
    Brown CH; Ziegler JL; Templeton C; Carbone PP
    Cancer; 1970 Aug; 26(2):462-7. PubMed ID: 5451221
    [No Abstract]   [Full Text] [Related]  

  • 14. Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.
    Morgan LR; Posey LE; Rainey J; Bickers J; Ryan D; Vial R; Hull EW
    Cancer Treat Rep; 1981; 65(7-8):693-5. PubMed ID: 6265084
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
    Itami S; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N; Nakagawa K
    Gan To Kagaku Ryoho; 1990 May; 17(5):1015-20. PubMed ID: 2159265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J; Brock N; Burkert H; Fichtner E
    Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Shepherd FA; Latreille J; Paul K; Eisenhauer E
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
    Irino S; Fujita J; Yamaji Y; Futami H; Hashimoto Y; Bungo M; Iuchi Y; Kamei M; Nakamura H; Hata Y
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2263-7. PubMed ID: 2544150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.